Evaluating the concordance between BICLA and SRI4 in patients with systemic lupus erythematosus from the placebo arms of the EXPLORER and ATHOS trials
BICLA and SRI4 may be discordant in SLE trials. Arthritis and rash were the primary drivers of the discordance, and serology influenced BICLA and SRI4 response, suggesting the need for evaluation of multiple efficacy endpoints rather than a single measure.
Authors
- Armando Turchetta (ORCID: https://orcid.org/0000-0001-6490-0110)
- Edward M Vital (ORCID: https://orcid.org/0000-0003-1637-4755)
- Oliver Meier (ORCID: https://orcid.org/0000-0003-4565-6815)
- Maria Dall’Era (ORCID: https://orcid.org/0000-0001-7439-2316)
- Jorge Alfonso Ross Terres (ORCID: https://orcid.org/0000-0003-3722-5062)
- Justine Maller (ORCID: https://orcid.org/0000-0001-6930-7375)
- Anca Askanase (ORCID: https://orcid.org/0000-0003-4597-5023)
- Huiyan Mao
Institutions
- Roche (Switzerland) (CH)
- University of Leeds (GB)
- University of California, San Francisco (US)
- Leeds Teaching Hospitals NHS Trust (GB)
- Columbia University Irving Medical Center (US)
- Roche (Canada) (CA)
- NIHR Leeds Musculoskeletal Biomedical Research Unit (GB)
Publication Details
- Journal
- Lupus Science & Medicine
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1136/lupus-2024-001483
- Citations
- 1
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 1.67
Funders
- Roche
- F. Hoffmann-La Roche